A Study to Evaluate Quality of Life Over Time in Patients Treated with CAR-T Cell Therapy Compared with Stem Cell Transplantation in Hematologic Malignancies

Overview

About this study

The purpose of this study is to evaluate quality of life over time in patients treated with CAR-T therapy compared with autologous and allogeneic stem cell transplant.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years

  • Patients with hematologic malignancies undergoing CAR-T cell therapy, autologous stem cell transplant or allogeneic stem cell transplant

  • Provide informed consent

  • Ability to complete questionnaire(s) in English by themselves or with assistance

 Exclusion Criteria:

  • None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Surbhi Sidana, M.B.B.S.

Closed for enrollment

Contact information:

Ann Engebretson L.P.N.

(507) 293-1965

Engebretson.Ann@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20436938

Mayo Clinic Footer